May 8, 2021
Business News

Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential


MIAMI–()–Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection.

As of May 2020, in the US, the CDC estimates between 39-55 million influenza related illnesses and more than 60,000 deaths are due to influenza. The observed illnesses and case fatalities are primarily due to the lack of effective antivirals and prophylactic vaccines…



Click here to view the original article.

Related Posts

You might also like ...

Regions Bank’s Ashley Garrison Recognized by American Banker Among Emerging Women in Leadership in Financial Services
Article feature image
Yale’s David Swensen Leaves Behind A Powerful Legacy In Investing – NPR
Article feature image
Tax refund delays could continue as backlog of tax returns is growing, tax advocate says – CBS News